Jingxin Pharmaceuticals: Signs Patent Licensing Agreement with Gedeon Richter Plc.

On the evening of August 7, Jingxin Pharmaceuticals announced that the company has signed a "Patent License Agreement" with Gedeon Richter Plc. Gedeon Richter will grant the company an exclusive patent license, allowing the company to develop, manufacture, and commercialize formulations and APIs of cariprazine hydrochloride within the licensed territory. Cariprazine hydrochloride is an atypical antipsychotic drug that acts as a partial agonist at dopamine D2 and D3 receptors. It is mainly used for the treatment of adult schizophrenia, acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, treatment of depressive episodes associated with bipolar I disorder in adults, and adjunctive treatment of severe depressive episodes in antidepressant therapy.